Editas Medicine to Participate in Upcoming Investor Conferences
Get Alerts EDIT Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:
- Wells Fargo Healthcare Conference
Format: One-on-one Meetings
Date: Wednesday, September 3
Location: Boston, MA
- Cantor Global Healthcare Conference
Format: Fireside Chat with Webcast and One-on-one Meetings
Date: Thursday, September 4
Time: 11:30 a.m. ET
Location: New York, NY
- Baird Global Healthcare Conference.
Format: Presentation and One-on-one Meetings
Date: Tuesday, September 9
Location: New York, NY
To access the live webcasts (where available) of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor and Media Contacts: [email protected] [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- Best Crypto to Buy Now Is Not ETH or SOL and Pepeto Proves Why Before
- Memecoin Launches Today: How MemeToro Uses AI Agents to Build Fair Launch Ecosystems
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Robert W Baird, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share